REG - Oxford Biomedica PLC - New Non-Exclusive LentiVector Licence with MolMed <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

07/06/2016 07:06

RNS Number : 3755A
Oxford Biomedica PLC
07 June 2016
Establishment of a New Non-Exclusive LentiVector Licence with MolMed 
Oxford, UK - 7 June 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, today announces that it has signed a new non-exclusive licence under Oxford BioMedica's LentiVector platform technology patents for manufacturing and development services with MolMed S.p.A ("MolMed") (MLM. MI). A previous retroviral patent agreement between Oxford BioMedica and MolMed has now expired.
John Dawson, CEO of Oxford BioMedica, commented: "This agreement with MolMed is a further endorsement of our dominant patent estate and of our unique LentiVector platform technology for state-of-the-art bioprocessing and development services. Oxford BioMedica is already a partner for leading companies in the gene and cell therapy sector including Novartis, Sanofi, GSK and Immune Design."
- Ends -
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton
Tel: +44 (0)20 3709 5700
Notes for editors
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 230 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCEAAKKEFSKEAF